The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

Transplantation. 2018 Jun;102(6):900-931. doi: 10.1097/TP.0000000000002191.


Despite recent advances, cytomegalovirus (CMV) infections remain one of the most common complications affecting solid organ transplant recipients, conveying higher risks of complications, graft loss, morbidity, and mortality. Research in the field and development of prior consensus guidelines supported by The Transplantation Society has allowed a more standardized approach to CMV management. An international multidisciplinary panel of experts was convened to expand and revise evidence and expert opinion-based consensus guidelines on CMV management including prevention, treatment, diagnostics, immunology, drug resistance, and pediatric issues. Highlights include advances in molecular and immunologic diagnostics, improved understanding of diagnostic thresholds, optimized methods of prevention, advances in the use of novel antiviral therapies and certain immunosuppressive agents, and more savvy approaches to treatment resistant/refractory disease. The following report summarizes the updated recommendations.

Publication types

  • Consensus Development Conference
  • Practice Guideline
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Consensus
  • Cytomegalovirus Infections / diagnosis
  • Cytomegalovirus Infections / drug therapy*
  • Cytomegalovirus Infections / immunology
  • Humans
  • Immunocompromised Host
  • Immunosuppressive Agents / adverse effects
  • Opportunistic Infections / diagnosis
  • Opportunistic Infections / drug therapy*
  • Opportunistic Infections / immunology
  • Organ Transplantation / adverse effects*
  • Organ Transplantation / standards
  • Risk Factors
  • Treatment Outcome


  • Antiviral Agents
  • Immunosuppressive Agents